Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Adaptive Biotechnologies stock

ADPT
US00650F1093
A2PLR5

Price

5.02
Today +/-
+0.32
Today %
+6.82 %

Adaptive Biotechnologies stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Adaptive Biotechnologies stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Adaptive Biotechnologies stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Adaptive Biotechnologies stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Adaptive Biotechnologies's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Adaptive Biotechnologies Stock Price History

DateAdaptive Biotechnologies Price
11/25/20245.02 undefined
11/22/20244.69 undefined
11/21/20244.37 undefined
11/20/20244.42 undefined
11/19/20244.48 undefined
11/18/20244.68 undefined
11/15/20245.08 undefined
11/14/20245.58 undefined
11/13/20245.92 undefined
11/12/20245.93 undefined
11/11/20246.49 undefined
11/8/20245.82 undefined
11/7/20245.63 undefined
11/6/20245.75 undefined
11/5/20245.58 undefined
11/4/20245.26 undefined
11/1/20245.31 undefined
10/31/20244.84 undefined
10/30/20245.06 undefined
10/29/20244.71 undefined
10/28/20244.67 undefined

Adaptive Biotechnologies Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Adaptive Biotechnologies, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adaptive Biotechnologies from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adaptive Biotechnologies’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Adaptive Biotechnologies. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Adaptive Biotechnologies’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Adaptive Biotechnologies’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adaptive Biotechnologies’s growth potential.

Adaptive Biotechnologies Revenue, EBIT and net profit per share

DateAdaptive Biotechnologies RevenueAdaptive Biotechnologies EBITAdaptive Biotechnologies Net Income
2026e268.86 M undefined-105.52 M undefined-101.86 M undefined
2025e215.46 M undefined-149.7 M undefined-140.56 M undefined
2024e181.31 M undefined-177.85 M undefined-167.84 M undefined
2023170.28 M undefined-201.61 M undefined-225.25 M undefined
2022185.3 M undefined-198.6 M undefined-200.2 M undefined
2021154.3 M undefined-209 M undefined-207.3 M undefined
202098.4 M undefined-152.8 M undefined-146.2 M undefined
201985.1 M undefined-78.4 M undefined-69.6 M undefined
201855.7 M undefined-49.8 M undefined-46.3 M undefined
201738.4 M undefined-43.7 M undefined-42.7 M undefined

Adaptive Biotechnologies Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e
38558598154185170181215268
-44.7454.5515.2957.1420.13-8.116.4718.7824.65
57.8965.4572.9476.5368.1868.6555.2951.9343.7235.07
2236627510512794000
-42-46-69-146-207-200-225-167-140-101
-9.5250.00111.5941.78-3.3812.50-25.78-16.17-27.86
118.5118.5125.2131.2140.4142.5144.38000
----------
Details

Keystats

ⓘ

Revenue and Growth

The Adaptive Biotechnologies Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Adaptive Biotechnologies is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2017201820192020202120222023
             
192.2165576.9688.3353.1498.2346.4
5.64.812.71017.440.137.97
0000000
4.87.89.114.119.314.514.45
2.73.114.114.5139.411.37
205.3180.7612.8726.9402.8562.2410.19
1419.160.4139172.9164.2120.32
8.90105.4118.5217.100
0000000
15.313.611.910.28.56.85.13
119119119119119119118.97
0.10.22.92.734.56.52
157.3151.9299.6389.4520.5294.5250.95
0.360.330.911.120.920.860.66
             
561.4560.900000.01
0.030.040.941.251.321.391.45
-249.4-295.9-365.5-511.6-718.9-919.1-1,144.33
-200-100700900-1,100-4,100215
0000000
336.8302.8571743.3604464.1308.4
21.84.53.23.38.17.72
4.17.210.426.929.637.431.61
14.913.863.475.180.964.348.69
0000000
0000000
2122.878.3105.2113.8109.888.02
0.30.336.6000130.66
0000000
4.46.8226.3268205.4282.7134.18
4.77.1262.9268205.4282.7264.84
25.729.9341.2373.2319.2392.5352.86
0.360.330.911.120.920.860.66
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Adaptive Biotechnologies provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Adaptive Biotechnologies's financial health and stability.

Assets

Adaptive Biotechnologies's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Adaptive Biotechnologies must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Adaptive Biotechnologies after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Adaptive Biotechnologies's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-42-46-68-146-207-200-225
5678142022
0000000
-5-1254-40-56-71-46
14212453100122155
0000008
0000000
-34-32205-149-192-183-156
-2-6-11-18-61-16-10
360-481-1171812129
387-470-9824319140
0000000
0000000
5013242932672
501319293271322
00-5001240
0000000
51-30432615-48-24
-37.4-38.6194.2-168.5-254.4-200.2-167.02
0000000

Adaptive Biotechnologies stock margins

The Adaptive Biotechnologies margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adaptive Biotechnologies. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adaptive Biotechnologies.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Adaptive Biotechnologies's sales revenue. A higher gross margin percentage indicates that the Adaptive Biotechnologies retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Adaptive Biotechnologies's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Adaptive Biotechnologies's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adaptive Biotechnologies's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adaptive Biotechnologies. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adaptive Biotechnologies's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Adaptive Biotechnologies Margin History

Adaptive Biotechnologies Gross marginAdaptive Biotechnologies Profit marginAdaptive Biotechnologies EBIT marginAdaptive Biotechnologies Profit margin
2026e55.63 %-39.25 %-37.89 %
2025e55.63 %-69.48 %-65.24 %
2024e55.63 %-98.09 %-92.57 %
202355.63 %-118.4 %-132.29 %
202268.75 %-107.18 %-108.04 %
202168.05 %-135.45 %-134.35 %
202077.13 %-155.28 %-148.58 %
201973.8 %-92.13 %-81.79 %
201864.63 %-89.41 %-83.12 %
201759.37 %-113.8 %-111.2 %

Adaptive Biotechnologies Stock Sales Revenue, EBIT, Earnings per Share

The Adaptive Biotechnologies earnings per share therefore indicates how much revenue Adaptive Biotechnologies has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adaptive Biotechnologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adaptive Biotechnologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adaptive Biotechnologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adaptive Biotechnologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Adaptive Biotechnologies Revenue, EBIT and net profit per share

DateAdaptive Biotechnologies Sales per ShareAdaptive Biotechnologies EBIT per shareAdaptive Biotechnologies Earnings per Share
2026e1.82 undefined0 undefined-0.69 undefined
2025e1.46 undefined0 undefined-0.95 undefined
2024e1.23 undefined0 undefined-1.14 undefined
20231.18 undefined-1.4 undefined-1.56 undefined
20221.3 undefined-1.39 undefined-1.4 undefined
20211.1 undefined-1.49 undefined-1.48 undefined
20200.75 undefined-1.16 undefined-1.11 undefined
20190.68 undefined-0.63 undefined-0.56 undefined
20180.47 undefined-0.42 undefined-0.39 undefined
20170.32 undefined-0.37 undefined-0.36 undefined

Adaptive Biotechnologies business model

Adaptive Biotechnologies Corp is a biotechnology company specializing in the discovery and development of therapies for various diseases. It was founded in 2009 by brothers Chad and Harlan Robins in Seattle, USA. Adaptive Biotechnologies Corp is a leading provider of immune sequencing technology and analysis of T-cell and B-cell receptors. The company's business model is based on the development of therapies through the analysis of patient samples. The company's artificial intelligence and machine learning make immune systems visible to fight pathogens. By creating an accurate profile of patients' immune systems, the company enables the development of personalized therapies tailored to the individual needs and disease profiles of patients. The company is divided into several divisions, including oncology, immunology, and research and development of therapeutics. In the field of oncology, Adaptive Biotechnologies Corp focuses on the discovery of cancer therapies by identifying T-cell receptor characteristics of patients who have responded to cancer treatments. The team at Adaptive Biotechnologies Corp works with various pharmaceutical and biotech companies to advance the discovery of cancer therapeutics. In the field of immunology, the company has also focused on the identification of rare and severe immune disorders to enable more targeted diagnostics and treatment. Adaptive Biotechnologies Corp provides immune and other research instruments and sample processing systems for the study of antigen-antibody interactions. In addition, the company has also developed its own products, including the ImmunTraCkeR® test system, which analyzes the immune response of critically ill patients to improve ongoing therapies or enable early detection of new diseases. Other products include the immunoSEQ® assay kit and the clonoSEQ® assay kit, which are used for sequencing patients' immune systems. These test systems allow for the detection of minimal residual routes of T-cell or B-cell receptors in patients' blood, enabling better monitoring of cancer and the creation of personalized treatment plans. Adaptive Biotechnologies Corp is particularly highly regarded in the pharmaceutical and biotech industry for novel therapeutics and biologics, and has already collaborated with many reputable companies including Genentech, Roche, and Microsoft. The company's mission is to accelerate progress in medical research and the development of new therapies to help patients around the world. In recent times, the company has played a crucial role in testing point-of-care COVID rapid tests. For example, it is working with universities such as the University of Pennsylvania to explore ways in which the tests can be utilized. The company is also developing its own COVID-19 tests that have undergone clinical testing. Overall, Adaptive Biotechnologies Corp is a successful biotechnology company with a unique focus on personalized medicine and therapies tailored to specific patient immune profiles. With its innovative products and services, as well as partnerships with industry leaders, the company has revolutionized the bio-IT world and become one of the leading companies in the industry. Adaptive Biotechnologies is one of the most popular companies on Eulerpool.com.

Adaptive Biotechnologies SWOT Analysis

Strengths

  • Advanced technology in immune-driven medicine and genomics.
  • Strong and diversified intellectual property portfolio.
  • Robust partnerships and collaborations with leading pharmaceutical and biotech companies.
  • Highly skilled and experienced team of scientists and clinicians.

Weaknesses

  • Dependence on a limited number of key partners for revenue generation.
  • Vulnerability to competition and rapid technological advancements in the industry.
  • Regulatory challenges and uncertainties in the field of personalized medicine.

Opportunities

  • Growing demand for personalized medicine and precision diagnostics.
  • Exploration of immune-driven therapies for various diseases with potential for high efficacy.
  • Expansion into emerging markets with unmet healthcare needs.

Threats

  • Intense competition from established and emerging players in the biotechnology sector.
  • Potential regulatory barriers and reimbursement challenges for novel diagnostic tests.
  • Economic downturns and fluctuations affecting healthcare spending and research funding.

Adaptive Biotechnologies Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Adaptive Biotechnologies Revenue by Segment

Segmente2022202120202019
Development support revenue-65.45 M USD54.44 M USD39.55 M USD
Service Revenue81.14 M USD---
Collaboration Revenue66.39 M USD---
Development revenue regulatory milestones-10 M USD2.5 M USD2 M USD
Regulatory Milestone Revenue6 M USD---

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Adaptive Biotechnologies Revenue by Segment

Segmente2022202120202019
Immune medicine service revenue700,000 USD---

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Adaptive Biotechnologies Revenue by Segment

Segmente2022202120202019
Sequencing revenue-78.9 M USD41.44 M USD43.52 M USD
Development revenue-300,000 USD56.94 M USD41.55 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Adaptive Biotechnologies Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Adaptive Biotechnologies historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Adaptive Biotechnologies shares outstanding

The number of shares was Adaptive Biotechnologies in 2023 — This indicates how many shares 144.383 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Adaptive Biotechnologies earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Adaptive Biotechnologies's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Adaptive Biotechnologies’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adaptive Biotechnologies's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Adaptive Biotechnologies.

Adaptive Biotechnologies latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.29 -0.22  (24.97 %)2024 Q3
6/30/2024-0.34 -0.31  (8.93 %)2024 Q2
3/31/2024-0.35 -0.33  (5.25 %)2024 Q1
12/31/2023-0.34 -0.3  (11.22 %)2023 Q4
9/30/2023-0.35 -0.35  (-1.24 %)2023 Q3
6/30/2023-0.35 -0.33  (6.65 %)2023 Q2
3/31/2023-0.38 -0.4  (-4.09 %)2023 Q1
12/31/2022-0.35 -0.28  (20.75 %)2022 Q4
9/30/2022-0.38 -0.32  (16.56 %)2022 Q3
6/30/2022-0.44 -0.37  (15.64 %)2022 Q2
1
2
3

Eulerpool ESG Scorecard© for the Adaptive Biotechnologies stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

36

👫 Social

70

🏛️ Governance

13

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Adaptive Biotechnologies shareholders

%
Name
Stocks
Change
Date
20.32369 % Viking Global Investors LP29,993,70806/30/2024
9.48638 % Rubric Capital Management LP14,000,0003,500,0006/30/2024
7.84157 % Matrix Capital Management Company, LP11,572,59006/30/2024
7.73276 % ARK Investment Management LLC11,412,000850,7046/30/2024
6.92974 % The Vanguard Group, Inc.10,226,911-2,619,4346/30/2024
6.47659 % BlackRock Institutional Trust Company, N.A.9,558,152263,3246/30/2024
6.36982 % Millennium Management LLC9,400,573138,2329/30/2024
4.67518 % Nikko Asset Management Co., Ltd.6,899,631722,9246/30/2024
2.65078 % MFS Investment Management3,912,0271,319,7096/30/2024
2.01531 % Aristotle Atlantic Partners, LLC2,974,188-18,3756/30/2024
1
2
3
4
5
...
10

Adaptive Biotechnologies Executives and Management Board

Mr. Chad Robins

(48)
Adaptive Biotechnologies Chairman of the Board, Chief Executive Officer, Co-Founder (since 2009)
Compensation 8.85 M

Dr. Harlan Robins

(50)
Adaptive Biotechnologies Co-Founder, Chief Scientific Officer
Compensation 8.46 M

Ms. Julie Rubinstein

(51)
Adaptive Biotechnologies President, Chief Operating Officer
Compensation 6.54 M

Mr. Tycho Peterson

(50)
Adaptive Biotechnologies Chief Financial Officer
Compensation 5.94 M

Dr. Sharon Benzeno

(49)
Adaptive Biotechnologies Chief Commercial Office - Immune Medicine
Compensation 3.24 M
1
2
3

Adaptive Biotechnologies Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Illumina Stock
Illumina
SupplierCustomer0,570,870,880,760,880,31
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,540,75-0,45-0,76-0,68-0,74
Microsoft Stock
Microsoft
SupplierCustomer0,520,410,290,83-0,21-0,72
Roche Holding Stock
Roche Holding
SupplierCustomer0,430,64-0,450,13-0,32-0,72
Professional Diversity Stock
Professional Diversity
SupplierCustomer0,320,740,810,400,860,60
Nykode Therapeutics Stock
Nykode Therapeutics
SupplierCustomer0,070,630,870,960,830,37
Laboratory Corp Stock
Laboratory Corp
SupplierCustomer0,040,470,800,910,63-0,51
1

Most common questions regarding Adaptive Biotechnologies

What values and corporate philosophy does Adaptive Biotechnologies represent?

Adaptive Biotechnologies Corp represents a strong commitment to revolutionizing the diagnosis and treatment of diseases through its innovative biotechnology solutions. The company's corporate philosophy revolves around harnessing the power of the adaptive immune system to develop precise and accurate diagnostic tests and personalized therapeutics for various diseases. Adaptive Biotechnologies Corp strives to improve patient outcomes by combining cutting-edge technology, computational biology, and extensive research expertise. With an unwavering focus on advancing precision medicine, Adaptive Biotechnologies Corp aims to empower healthcare professionals with the tools they need to make informed decisions and improve the lives of patients.

In which countries and regions is Adaptive Biotechnologies primarily present?

Adaptive Biotechnologies Corp is primarily present in the United States.

What significant milestones has the company Adaptive Biotechnologies achieved?

Some significant milestones achieved by Adaptive Biotechnologies Corp include the successful completion of their initial public offering (IPO) in June 2019, raising approximately $345 million. They have also entered into collaborations and partnerships with notable organizations, such as Genentech, Microsoft, and Amgen, among others. Adaptive Biotechnologies Corp has made significant advancements in deciphering the adaptive immune system with their proprietary immune medicine platform. This has led to the development of groundbreaking diagnostic tools and therapeutics for various diseases, including cancer. They continue to expand their reach globally and are committed to advancing precision medicine through their innovative approach to harnessing the power of the immune system.

What is the history and background of the company Adaptive Biotechnologies?

Adaptive Biotechnologies Corp is a healthcare company specializing in decoding the adaptive immune system to improve patient care. Founded in 2009 by Chad Robins and Harlan Robins, the company's innovative approach focuses on combining high-throughput sequencing with advanced bioinformatics to study the immune system and enable discoveries in various disease areas. Adaptive Bio has collaborations with leading pharmaceutical companies and research institutions worldwide. With its deep understanding of the adaptive immune system, the company aims to develop revolutionary diagnostics and therapies for diseases like cancer, autoimmune disorders, and infectious diseases. Adaptive Biotechnologies Corp is committed to transforming medicine through its cutting-edge technologies and unique insights into the immune system.

Who are the main competitors of Adaptive Biotechnologies in the market?

Adaptive Biotechnologies Corp faces competition from various companies in the market. Some notable competitors include Pacific Biosciences of California Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V. These companies also operate in the field of biotechnology, focusing on next-generation sequencing technologies and providing molecular diagnostic solutions. However, Adaptive Biotechnologies Corp distinguishes itself through its innovative and proprietary immune medicine platform, enabling the study of immune systems. By leveraging its unique technology, Adaptive Biotechnologies Corp maintains a competitive edge in the market.

In which industries is Adaptive Biotechnologies primarily active?

Adaptive Biotechnologies Corp is primarily active in the biotechnology industry.

What is the business model of Adaptive Biotechnologies?

The business model of Adaptive Biotechnologies Corp revolves around leveraging their proprietary immune medicine platform to develop and commercialize innovative diagnostic tests and therapeutics for various diseases. By using high-throughput sequencing to study the adaptive immune system, the company aims to understand and decode the high complexity of immune responses. This enables them to identify and analyze the biomarkers related to various diseases, including cancer and infectious diseases, resulting in the development of targeted diagnostic tools and potential treatment options. With their focus on precision medicine, Adaptive Biotechnologies Corp aims to improve patient outcomes and contribute to the advancement of personalized healthcare.

What is the P/E ratio of Adaptive Biotechnologies 2024?

The Adaptive Biotechnologies P/E ratio is -4.32.

What is the P/S ratio of Adaptive Biotechnologies 2024?

The Adaptive Biotechnologies P/S ratio is 4.

What is the Quality Investing of Adaptive Biotechnologies?

The Quality Investing for Adaptive Biotechnologies is 3/10.

What is the revenue of Adaptive Biotechnologies 2024?

The expected Adaptive Biotechnologies revenue is 181.31 M USD.

How high is the profit of Adaptive Biotechnologies 2024?

The expected Adaptive Biotechnologies profit is -167.84 M USD.

What is the business model of Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a biomedical company that focuses on the development of diagnostic tests and therapies to combat cancer and infectious diseases. The company was founded in 2009 and is headquartered in Seattle, Washington.

What is the Adaptive Biotechnologies dividend?

Adaptive Biotechnologies pays a dividend of 0 USD distributed over payouts per year.

How often does Adaptive Biotechnologies pay dividends?

The dividend cannot currently be calculated for Adaptive Biotechnologies or the company does not pay out a dividend.

What is the Adaptive Biotechnologies ISIN?

The ISIN of Adaptive Biotechnologies is US00650F1093.

What is the Adaptive Biotechnologies WKN?

The WKN of Adaptive Biotechnologies is A2PLR5.

What is the Adaptive Biotechnologies ticker?

The ticker of Adaptive Biotechnologies is ADPT.

How much dividend does Adaptive Biotechnologies pay?

Over the past 12 months, Adaptive Biotechnologies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Adaptive Biotechnologies is expected to pay a dividend of 0 USD.

What is the dividend yield of Adaptive Biotechnologies?

The current dividend yield of Adaptive Biotechnologies is .

When does Adaptive Biotechnologies pay dividends?

Adaptive Biotechnologies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Adaptive Biotechnologies?

Adaptive Biotechnologies paid dividends every year for the past 0 years.

What is the dividend of Adaptive Biotechnologies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Adaptive Biotechnologies located?

Adaptive Biotechnologies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Adaptive Biotechnologies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Adaptive Biotechnologies from 11/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/25/2024.

When did Adaptive Biotechnologies pay the last dividend?

The last dividend was paid out on 11/25/2024.

What was the dividend of Adaptive Biotechnologies in the year 2023?

In the year 2023, Adaptive Biotechnologies distributed 0 USD as dividends.

In which currency does Adaptive Biotechnologies pay out the dividend?

The dividends of Adaptive Biotechnologies are distributed in USD.

All fundamentals about Adaptive Biotechnologies

Our stock analysis for Adaptive Biotechnologies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adaptive Biotechnologies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.